Literature DB >> 11026565

1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration.

V Sung1, D Feldman.   

Abstract

1,25-Dihydroxyvitamin-D3 [1,25(OH)2D3], the active hormonal metabolite of vitamin D, acts through a specific nuclear receptor to inhibit proliferation and promote differentiation of several tumor cell types including the LNCaP, DU145 and PC-3 prostate cancer cell lines as well as primary prostate tumor lines. 1,25(OH)2D3 can also decrease invasion of breast and prostate cancer cell lines in vitro. We confirm this latter finding in the DU145 and PC-3 prostate cancer cell lines, and further show that 1,25(OH)2D3 inhibits overall invasion, cell adhesion and migration to the basement membrane matrix protein laminin. These changes appear to be due in part to a 1,25(OH)2D3-induced decrease in expression of alpha6 and beta4 integrins, both of which are receptors for laminin and associated with increased migration and invasion of prostate cancer cells in vitro. Blocking function of these particular integrins with antibodies inhibits both adhesion and migration of the cells. Collectively, these data demonstrate that 1,25(OH)2D3, in addition to decreasing proliferation of tumor cells, can also inhibit prostate cancer cell invasion through modulation of select cell surface adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11026565     DOI: 10.1016/s0303-7207(00)00226-4

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  31 in total

1.  The vitamin D receptor regulates rheumatoid arthritis synovial fibroblast invasion and morphology.

Authors:  Teresina Laragione; Anish Shah; Pércio S Gulko
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

2.  Vitamin d for the management of prostate cancer.

Authors:  Masood A Khan; Alan W Partin
Journal:  Rev Urol       Date:  2004

3.  Suppression of prostate cancer cell rolling and adhesion to endothelium by 1α,25-dihydroxyvitamin D3.

Authors:  Jong-Wei Hsu; Sayeda Yasmin-Karim; Michael R King; Joel C Wojciechowski; Deanne Mickelsen; Martha L Blair; Huei-Ju Ting; Wen-Lung Ma; Yi-Fen Lee
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 4.  24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics.

Authors:  Wei Luo; Pamela A Hershberger; Donald L Trump; Candace S Johnson
Journal:  J Steroid Biochem Mol Biol       Date:  2012-10-08       Impact factor: 4.292

Review 5.  Vitamin D and cancer: the promise not yet fulfilled.

Authors:  Daniel D Bikle
Journal:  Endocrine       Date:  2014-01-09       Impact factor: 3.633

6.  1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

Authors:  Michele N Washington; Nancy L Weigel
Journal:  Endocrinology       Date:  2010-02-10       Impact factor: 4.736

Review 7.  Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.

Authors:  Tomasz M Beer; Anne Myrthue; Kristine M Eilers
Journal:  World J Urol       Date:  2005-01-25       Impact factor: 4.226

8.  Retinoids modulate expression of the endocytic partners megalin, cubilin, and disabled-2 and uptake of vitamin D-binding protein in human mammary cells.

Authors:  Timothy M Chlon; David A Taffany; Joellen Welsh; Matthew J Rowling
Journal:  J Nutr       Date:  2008-07       Impact factor: 4.798

9.  The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells.

Authors:  Sara Marchiani; Lorella Bonaccorsi; Pietro Ferruzzi; Clara Crescioli; Monica Muratori; Luciano Adorini; Gianni Forti; Mario Maggi; Elisabetta Baldi
Journal:  J Cancer Res Clin Oncol       Date:  2006-02-17       Impact factor: 4.553

10.  Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface.

Authors:  Boris Novakovic; Mandy Sibson; Hong Kiat Ng; Ursula Manuelpillai; Vardhman Rakyan; Thomas Down; Stephan Beck; Thierry Fournier; Danielle Evain-Brion; Eva Dimitriadis; Jeffrey M Craig; Ruth Morley; Richard Saffery
Journal:  J Biol Chem       Date:  2009-02-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.